Upadacitinib versus adalimumab on routine assessment of patient index data 3 (rapid3) in patients with psoriatic arthritis.

Research output: Contribution to conference › Abstract › peer-review

Original language	Undefined/Unknown
Publication status	Published - 1 Jul 2022

Cite this

@conference{71751163a56240d390256d4c5d5f9b33,

title = "Upadacitinib versus adalimumab on routine assessment of patient index data 3 (rapid3) in patients with psoriatic arthritis.",

author = "L Coates and A Kavanaugh and E Mcdearmon-Blondell and A Mandelin and T Gao and W Tillett",

year = "2022",

month = jul,

day = "1",

language = "Undefined/Unknown",

}

TY - CONF

T1 - Upadacitinib versus adalimumab on routine assessment of patient index data 3 (rapid3) in patients with psoriatic arthritis.

AU - Coates, L

AU - Kavanaugh, A

AU - Mcdearmon-Blondell, E

AU - Mandelin, A

AU - Gao, T

AU - Tillett, W

PY - 2022/7/1

Y1 - 2022/7/1

UR - http://scientific.sparx-ip.net/archiveeular/?searchfor=tillett&view=1&c=a&item=2022POS1050

M3 - Abstract

ER -